Table 3:

Outcomes after hematopoietic cell transplant in t-AML patients

	Total patients	Age (median, range)	Overall survival (%)	Non-relapse or treatment- related mortality (%)	Relapse (%)
Sengsayadeth [64]	4997	58 (IQR, 50-64)	2-yr survival: 45	2-yr: 27	2-yr: 34%
Alam [16]	65	53 (19-69)	2-yr: 34*	2-yr: 31	2-yr: patients <60 years: 30, >60 years: 36
Litzow [26]†	868	40 (4-72)	1-yr: 32, 5-yr 21	1-yr: 41	1-yr: 27, 5-yr: 31
Yakoub-Agha [65]	70		2-yr: 30	2-yr: 49	2-yr: 42
Kroger [66]†	461	40 (3-69)	3-yr: 35	3-yr: 37	3-yr: 31
Finke [88]	79	58 (20-76)	5-yr: 38, 10-yr 24%	5-yr: 23, 10-yr 32	5-yr: 42, 10-yr: 44

^*Favorable, intermediate, and unfavorable cytogenetics had 2-year overall survival of 53%, 44%, and 21% respectively.

^†includes both t-AML and t-MDS

CR- complete remission, IQR- Inter-quartile range, t-AML- therapy related acute myeloid leukemia, t-MDS- therapy related myelodysplastic syndrome